NXLHealthcare · Medical DevicesNXL Stock Forecast: Nexalin Technology, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Nexalin Technology, Inc. hold a median 12-month price target of $2 — +448.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
NXL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Nexalin Technology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Quality (5): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Nexalin Technology, Inc. — and when they’d sell — is the membership.
NXL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NXL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +448.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Mar 2025 | Maxim Group | Upgrade | Buy | $5.00 |
| 5 Dec 2024 | Maxim Group | Downgrade | Hold | — |
| 9 Oct 2024 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NXL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Nexalin Technology, Inc. (NXL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.7×
- Price / sales
- 27.0×
- Price / book
- 2.4×
- EV / EBITDA
- −0.5×
Cheaper than 80% of US stocks
Cheaper than 7% of US stocks
Cheaper than 40% of US stocks
Cheaper than 65% of US stocks
- Revenue growth (YoY)
- −63.6%
- Earnings growth (YoY)
- −63.5%
- Gross margin
- 87.8%
- Operating margin
- −14179.9%
- Net margin
- 79.7%
Higher than 4% of US stocks
Higher than 7% of US stocks
Higher than 96% of US stocks
Higher than 2% of US stocks
Higher than 98% of US stocks
- Return on equity
- −319.7%
- Return on assets
- −161.1%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
NXL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NXL appears on the weeks it earns a place.
Frequently asked questions about NXL stock
What is the NXL stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Nexalin Technology, Inc. have a median 12-month price target of $2, with estimates ranging from $2 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NXL stock a buy right now?
Of the 1 analysts covering Nexalin Technology, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nexalin Technology, Inc. 23 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NXL?
As at 1 Aug 2026, Nexalin Technology, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
Will NXL stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +448.1% from the last close, and Ticker Nerd's factor model ranks Nexalin Technology, Inc. 23 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NXL stock forecast for 2030?
No analyst covering Nexalin Technology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NXL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.
How has NXL stock performed over the past year?
Nexalin Technology, Inc. returned -63.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Nexalin Technology, Inc. do?
Nexalin Technology Inc. is a healthcare technology company that designs and develops non-invasive neurostimulation medical devices focused on mental health.
About Nexalin Technology, Inc.
Nexalin Technology Inc. is a healthcare technology company that designs and develops non-invasive neurostimulation medical devices focused on mental health. The company’s primary products are neurostimulation systems intended to help treat conditions such as anxiety, depression, and insomnia by delivering a proprietary electrical waveform to targeted areas of the brain without the use of drugs. Nexalin Technology Inc. positions its devices as easy-to-administer solutions for clinicians and treatment centers, aiming to integrate into existing mental health care workflows. Its flagship Generation 1 device is a cranial electrotherapy stimulation system classified as a Class II medical device by the U.S. Food and Drug Administration. Headquartered in Houston, Texas and founded in 2010, Nexalin Technology Inc. operates within the medical device segment of the healthcare sector, serving mental health providers seeking alternative or adjunctive approaches to conventional pharmacological and psychotherapeutic treatments.
CEO Mr. Mark White · 8 employees · United States · https://www.nexalin.com